This article is more than 5 years old. Information may no longer be current.

VIDEO: Certain antiplatelet therapies more beneficial for patients with vs. without diabetes

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PHILADELPHIA —In this Endocrine Today video perspective, Deepak Bhatt, MD, MPH, from Brigham and Women’s Hospital, discusses his presentation on the use of antiplatelet therapy for patients with diabetes at the Heart in Diabetes Medical Conference.

Highlighting data for IV glycoprotein IIb/IIIa inhibitors and dual antiplatelet therapies, Bhatt reviewed the diabetic subgroups from trials such as the CAPRI, CHARISMA and PEGASUS–TIMI 54, in which patients with diabetes attained higher benefit from potent antiplatelet therapy vs. patients without diabetes.

“All those trials with their respective subgroup of patients with diabetes for the most part showed at least the same degree of benefit as non-diabetic patients and in most cases, greater absolute benefit given their greater absolute risk,” Bhatt said. “A consistent theme [is] that diabetic patients seem to benefit a bit more from antiplatelet therapy than non-diabetic patients, though, not clear that that's any fundamental biological reason, but rather, just because diabetic patients, especially in the secondary prevention universe, have higher rates of baseline ischemic events.”